
ELV Stock Forecast & Price Target
ELV Analyst Ratings
Bulls say
Elevance Health is uniquely positioned as the largest provider of Blue Cross Blue Shield branded coverage in 14 states and has also expanded its reach through acquisitions in government-sponsored programs, such as Medicaid and Medicare Advantage. Its diverse portfolio and strong growth potential in multiple business lines make it an attractive investment choice. Despite known pressures from Medicaid and Carelon, its management's commitment to returning to >12% EPS growth in 2027, opportunistic capital deployment, and an expected improvement in MA and ACA markets, make it a solid choice for investors.
Bears say
Elevance Health is facing a negative outlook due to several reasons. These include a shifting mix and lower percentage margins in its CarelonRx segment, risks related to the Affordable Care Act and Medicaid cost utilization, and the company's revised long-term margin targets. Additionally, the need for continued investment in AI/tech and Carelon scalability may result in a significant SG&A expense in 2026.
This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELV Analyst Forecast & Price Prediction
Start investing in ELV
Order type
Buy in
Order amount
Est. shares
0 shares